CSRC approves Weitongli's IPO registration on the Shenzhen Stock Exchange
On January 30th, the China Securities Regulatory Commission issued the "Approval of Beijing Weitongli Electric Co., Ltd.'s First Public Offering of Stocks Registration".
On January 30th, the China Securities Regulatory Commission issued the "Approval for the Initial Public Offering of Beijing Weitongli Electric Co., Ltd." It is reported that Weitongli plans to list on the main board of the Shenzhen Stock Exchange, with Zhongtai as its sponsoring institution, intending to raise 1.59374 billion yuan.
The prospectus shows that Weitongli's main business is the research and development, production, and sales of series of electrical connection products such as hard connections, flexible connections, contact components, laminated busbars, CCS, and synchronous decomposers, as well as other products. The company is committed to providing high-performance electrical connection products and customized product solutions tailored to the individual needs of customers in various sectors worldwide, making electrical connections safer, more reliable, greener, and smarter.
Weitongli focuses on serving high-end customers in the electrical connection product market, with its products widely recognized by mainstream customers in various application fields. In the electric power and electrical engineering field, the company supplies products to Siemens, Schneider, ABB, Hitachi Energy, GE, etc.; in the new energy vehicle field, products are supplied to BYD Company Limited, StratiS, LEAPMOTOR, CALB, Sunwoda Electronic, Honeycomb Energy, Farasis Energy (Gan Zhou) Co., Ltd., etc.; in the wind and solar energy storage field, products are supplied to Goldwind Science & Technology, Ming Yang Smart Energy, Veidai Technology, Sungrow Power Supply, Solingen Electric, Point Energy, Delta Electronics, etc.; in the rail transportation field, products are supplied to CRRC Corporation, Westinghouse Brake, Alstom, etc. The above customers are all leading companies in their respective industries or are Fortune 500 companies.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


